Climb Bio Inc.
Organization details
- Legal name
- Climb Bio Inc.
- Former names
- Eliem Therapeutics, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Wellesley Hills
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CLYM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001768446
- EIN
- 83-2273741
Board of directors
-
Adam Joseph Rosenberg · DirectorSince 2023
-
Alexander Cumbo · DirectorSince 2025
-
Andrew David Levin · Director · Executive ChairmanSince 2023
-
Aoife Brennan · Director · President and CEOSince 2024
-
Breanna Maurine Celebi · DirectorSince 2026
-
Douglas E. Williams · DirectorSince 2024
-
Judith Dunn · DirectorSince 2023
-
Kimberlee C. Drapkin · DirectorSince 2025
-
Liam Ratcliffe · DirectorSince 2023
- Since 2023
- Since 2023
-
Simon Tate · DirectorSince 2023
-
Stephen Basil Thomas · DirectorSince 2024
Chief executives
Director election results
Annual meeting of June 5, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
89.3%
Board connections
8 of this board's directors also sit on 32 other boards. 32 are in the same sector.
-
Vor Biopharma Inc. Same sectorvia Alexander Cumbo, Andrew David Levin, Peter Kolchinsky and Rajeev M. Shah
-
Acumen Pharmaceuticals Inc. Same sectorvia Kimberlee C. Drapkin, Peter Kolchinsky and Rajeev M. Shah
-
LENZ Therapeutics Inc. Same sectorvia Kimberlee C. Drapkin, Peter Kolchinsky and Rajeev M. Shah
-
Solid Biosciences Inc. Same sectorvia Alexander Cumbo, Peter Kolchinsky and Rajeev M. Shah
-
ARS Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acrivon Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Artiva Biotherapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bambusa Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bicara Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Black Diamond Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Evommune Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Freenome Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Hemab Therapeutics Holdings Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Jade Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Janux Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Mineralys Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Nkarta Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Parabilis Medicines Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
PepGen Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Septerna Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Sionna Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
SpyGlass Pharma Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Tyra Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Wave Life Sciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Werewolf Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
CAMP4 Therapeutics Corporation Same sectorvia Douglas E. Williams
-
Disc Medicine Inc. Same sectorvia Liam Ratcliffe
-
Kyntra Bio Inc. Same sectorvia Aoife Brennan
-
OnKure Therapeutics Inc. Same sectorvia Liam Ratcliffe
-
Stoke Therapeutics Inc. Same sectorvia Alexander Cumbo
-
Upstream Bio Inc. Same sectorvia Liam Ratcliffe
-
Xilio Therapeutics Inc. Same sectorvia Aoife Brennan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $779,626
- 3 purchases by 2 insiders
- Sold, last 12 months
- $2,652,942
- 6 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 28, 2026 | RA Capital Nexus Fund, L.P. Director | Option exercise | +10,000 | $3.46 | $34,600 |
| Sep 28, 2026 | RA Capital Nexus Fund, L.P. Director | Option exercise | +10,000 | $3.00 | $30,000 |
| Sep 28, 2026 | RA Capital Nexus Fund, L.P. Director | Option exercise | +10,000 | $7.89 | $78,900 |
| Sep 28, 2026 | RA Capital Nexus Fund, L.P. Director | Option exercise | +40,000 | $1.29 | $51,600 |
| Sep 15, 2026 | Stephen Basil Thomas Director | Open-market sale | −100,000 | $13.67 | $1,367,000 |
| Jun 29, 2026 | Aoife Brennan Director, Officer (President and CEO) | Open-market sale | −30,902 | $13.17 | $406,979 |
| Jun 27, 2026 | Aoife Brennan Director, Officer (President and CEO) | Option exercise | +68,750 | — | — |
| Feb 26, 2026 | Stephen Basil Thomas Director | Open-market sale | −16,313 | $7.01 | $114,354 |
| Feb 25, 2026 | Stephen Basil Thomas Director | Open-market sale | −33,687 | $7.00 | $235,809 |
| Feb 13, 2026 | Stephen Basil Thomas Director | Open-market sale | −10,000 | $5.81 | $58,100 |
| Feb 12, 2026 | Stephen Basil Thomas Director | Open-market sale | −90,000 | $5.23 | $470,700 |
| Jan 5, 2026 | RA Capital Healthcare Fund LP Director, 10% owner | Open-market purchase | +7,111 | $3.50 | $24,889 |
| Dec 12, 2025 | Peter Kolchinsky Director, 10% owner | Open-market purchase | +101,462 | $2.86 | $290,181 |
| Dec 11, 2025 | Peter Kolchinsky Director, 10% owner | Sold back to the company | −20,440,000 | — | — |
| Dec 11, 2025 | Peter Kolchinsky Director, 10% owner | Open-market purchase | +213,099 | $2.18 | $464,556 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Climb Bio Inc.
Who is the CEO of Climb Bio Inc.?
Aoife Brennan has been Climb Bio Inc.'s President and CEO since June 2024.
How many directors are on Climb Bio Inc.'s board?
Climb Bio Inc.'s board has 13 directors: Adam Joseph Rosenberg, Alexander Cumbo, Andrew David Levin, Aoife Brennan, Breanna Maurine Celebi, Douglas E. Williams, Judith Dunn, Kimberlee C. Drapkin, Liam Ratcliffe, Peter Kolchinsky and 3 others.
Are Climb Bio Inc. insiders buying or selling shares?
Over the last 12 months, Climb Bio Inc. insiders bought $779,626 of shares in 3 purchases and sold $2.7 million of shares in 6 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="climb-bio-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.